Posted on February 28, 2019 by Sitemaster
In a not entirely surprising set of findings, data from a relatively large registry study — to be presented at an upcoming meeting of the American Association of Cancer Research (AACR) — suggest that treatment with abiraterone acetate raises risk for cardiovascular-related mortality among prostate cancer patients with known cardiovascular risk factors. … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, cardiovascular, hospitalizaton, mortality, real world, risk, trials | 4 Comments »
Posted on September 5, 2017 by Sitemaster
A few days ago we commented briefly on a paper by Haque et al. on the risk for cardiovascular complications and side effects of ADT in men initially diagnosed with localized prostate cancer and supposedly managed, initially, on active surveillance. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, cardiovascular, deprivation, side effect | 1 Comment »
Posted on September 3, 2017 by Sitemaster
Not so long ago, we addressed the question of whether first-line androgen deprivation therapy (ADT) was really an appropriate form of care for any man with localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen, arrhythmia, cardiovascular, deprivation, failure, heart, risk | 9 Comments »
Posted on April 28, 2016 by Sitemaster
A new paper from a panel of experts in the UK has suggested that the use of LHRH antagonists (e.g., degarelix) may be more appropriate than the use of LHRH agonists (e.g., leuprolide acetate of goserelin acetate) in some prostate cancer patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, antagonist, cardiovascular, LHRH, risk | 3 Comments »
Posted on February 5, 2016 by Sitemaster
Based on a specific case study, a new paper in Circulation by a group of clinicians at Vanderbilt University Medical Center describes their program designed to reduce risk of death from cardiovascular disease for prostate cancer patients on androgen deprivation therapy (ADT). … READ MORE …
Filed under: Uncategorized | Tagged: ADT, androgen, cardiovascular, deprivation, heart, risk, survival | Leave a comment »
Posted on January 5, 2016 by Sitemaster
A new trial to be discussed at the Genitourinary Cancers Symposium is the RADICAL-PC trial, designed to give us a greater understanding of the roles of androgen deprivation (ADT) and other factors in causing cardiovascular disease in high-risk prostate cancer patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, cardiovascular, deprivation, disease, Management, risk, Treatment, trial | 1 Comment »
Posted on October 21, 2015 by Sitemaster
Some recent randomized clinical trials have shown that adding androgen deprivation therapy (ADT) to radiation therapy can improve outcomes in some circumstances. However, … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, cardiovascular, radiation, risk, side effect | 2 Comments »
Posted on August 5, 2015 by Sitemaster
A newly published paper in BJU International has expanded our understanding of the cardiovascular risks associated with the use of androgen deprivation therapy (ADT) — most particularly in older men treated with ADT as their first-line form of therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, cardiac, cardiovascular, LHRH agonist, orchiectomy, risk, side effects | 3 Comments »
Posted on April 2, 2015 by Sitemaster
As our regular readers will be well aware, the topic of risk for cardiovascular disease among prostate cancer patients being treated with any form of androgen deprivation therapy (ADT, also known as “hormone” therapy) comes up on a regular basis. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: ADT, androgen, cardiovascular, deprivation, hormone, risk | 3 Comments »
Posted on March 25, 2013 by Sitemaster
There has been significant media coverage of a recent article in the journal Circulation. The article reports that individuals enrolled in the Atherosclerosis Risk in Communities (ARIC) study were able to cut their overall risk for cancer by 51 percent. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Prevention, Risk | Tagged: cancer, cardiovascular, Diagnosis, diet, lifestyle, mortality, risk | Leave a comment »
Posted on February 28, 2013 by Sitemaster
Data from two studies just published by a team of Norwegian researchers have suggested the possibility that men taking β-blockers for other (e.g., cardiovascular) conditions may have an increased survival benefit compared to other men who are diagnosed with and treated for high-risk or metastatic prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ADT, androgen, beta, blocker, cardiovascular, deprivation, metastatic | Leave a comment »
Posted on August 7, 2012 by Sitemaster
The degree to which modern forms of androgen deprivation therapy (ADT) increase risk for serious cardiovascular side effects (and death from heart attacks in particular) is a complex and controversial subject, and there are few really good prospective data on which to base sound clinical decision-making. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, cardiovascular, deprivation, mortality, risk | Leave a comment »
Posted on December 7, 2011 by Sitemaster
So a meta-analysis of data from multiple clinical trials has now shown rigorously something that we did, in fact, already know … that there was no excess incidence of cardiovascular mortality associated with androgen deprivation therapy (ADT) in clinical trials conducted to date in which use of ADT was compared to a placebo. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, cardiovascular, meta-analysis, mortality, risk | 2 Comments »
Posted on October 21, 2010 by Sitemaster
According to a media release from the U.S. Food and Drug Administration (FDA) yesterday, the agency has asked manufacturers of the class of drugs known as luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists to include warnings about risk for cardiovascular disease and diabetes in product labeling for these drugs. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, cardiovascular, GnRH, LHRH, metabolic, risk, side effect | 3 Comments »
Posted on May 3, 2010 by Sitemaster
For many years it has been understood by specialists that hormonal treatment of prostate cancer patients with luteinizing hormone releasing hormone (LHRH) agonists — also known as gonadatropin releasing hormone or GnRH agonists — is associated with metabolic side effects that include risks for cardiovascular disease and diabetes. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, androgen deprivation therapy, cardiovascular, GnRH, LHRH, metabolic, side effect | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 